利妥昔单抗注射液相关性肺炎的Meta分析(4)
[ 7 ] MALEY A， WARREN M， HABERMAN I， et al. Rituximab combined with conventional therapy versus conventional therapy alone for the treatment of mucous membrane pemphigoid (MMP)[J]. J Am Acad Dermatol， 2016， 74(5)：835-844.
[ 8 ] SAUTENET B，BLANCHO G，B?CHLER M，et al. One- year results of the dffects of rituximab on acute antibody-mediated rejection in renal transplantation： RITUX ERAH， a multicenter double-blind randomized placebo-Controlled trial[J]. Transplantation， 2016， 100(2)：391-399.
, http://www.100md.com
[ 9 ] DAHAN K， DEBIEC H， PLAISIER E， et al. Rituximab for severe membranous nephropathy： a 6-month trial with extended follow-up[J]. J Am Soc Nephrol，2016，28(1)：348-358.
[10] 張燕萍， 周晓慧， 张丽，等. 利妥昔单抗联合改良 CHOP方案治疗非霍奇金淋巴瘤的临床疗效及安全性评价[J]. 中国临床药理学杂志，2015(12)：1109-1111.
[11] 周婕， 青胜兰， 徐锋，等. 利妥昔单抗注射液联合化疗治疗B 细胞非霍奇金淋巴瘤的疗效观察[J]. 现代生物医学进展， 2015，15(31)：6143-6145.
[12] STAN MN， GARRITY JA， CARRANZA LEON BG， et al. Randomized controlled trial of rituximab in patients with Graves’orbitopathy[J]. J Clin Endocrinol Metab，2014，100(2)：432-441.
, 百拇医药
[13] GLASS B， HASENKAMP J， WULF G， et al. Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHLR3)： an open-label，randomised，phase 2 trial[J]. Lancet Oncol，2014，15(7)：757-766.
[14] BIRGENS H， FREDERIKSEN H， HASSELBALC HC ， et al. A phaseⅢrandomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia[J]. Br J Haematol，2013，163(3)：393-399.
, 百拇医药
[15] SNELLER MC，HU Z， LANGFORD CA. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C-associated cryoglobulinemic vasculitis[J]. Arthritis Rheum， 2012， 64(3)： 835-842.
[16] DE VITA S， QUARTUCCIO L， ISOLA M， et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis[J]. Arthritis Rheum， 2012， 64(3)： 843-853.
[17] KETTERER N，COIFFIER B， THIEBLEMONT C， et al. PhaseⅢstudy of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B)[J]. Ann Oncol， 2012， 24(4)：1032-1037.
, 百拇医药
[18] GREENWALD MW， SHERGY WJ， KAINE JL， et al. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis[J]. Arthritis Rheum，2011， 63(3)： 622-632.
[19] MEIJER JM， MEINERS PM， VISSINK A， et al. Effectiveness of rituximab treatment in primary Sj?gren’s syndrome[J]. Arthritis Rheum， 2010， 62(4)： 960-968., http://www.100md.com(白浩 孙朴 陈霞)
[ 8 ] SAUTENET B，BLANCHO G，B?CHLER M，et al. One- year results of the dffects of rituximab on acute antibody-mediated rejection in renal transplantation： RITUX ERAH， a multicenter double-blind randomized placebo-Controlled trial[J]. Transplantation， 2016， 100(2)：391-399.
, http://www.100md.com
[ 9 ] DAHAN K， DEBIEC H， PLAISIER E， et al. Rituximab for severe membranous nephropathy： a 6-month trial with extended follow-up[J]. J Am Soc Nephrol，2016，28(1)：348-358.
[10] 張燕萍， 周晓慧， 张丽，等. 利妥昔单抗联合改良 CHOP方案治疗非霍奇金淋巴瘤的临床疗效及安全性评价[J]. 中国临床药理学杂志，2015(12)：1109-1111.
[11] 周婕， 青胜兰， 徐锋，等. 利妥昔单抗注射液联合化疗治疗B 细胞非霍奇金淋巴瘤的疗效观察[J]. 现代生物医学进展， 2015，15(31)：6143-6145.
[12] STAN MN， GARRITY JA， CARRANZA LEON BG， et al. Randomized controlled trial of rituximab in patients with Graves’orbitopathy[J]. J Clin Endocrinol Metab，2014，100(2)：432-441.
, 百拇医药
[13] GLASS B， HASENKAMP J， WULF G， et al. Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHLR3)： an open-label，randomised，phase 2 trial[J]. Lancet Oncol，2014，15(7)：757-766.
[14] BIRGENS H， FREDERIKSEN H， HASSELBALC HC ， et al. A phaseⅢrandomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia[J]. Br J Haematol，2013，163(3)：393-399.
, 百拇医药
[15] SNELLER MC，HU Z， LANGFORD CA. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C-associated cryoglobulinemic vasculitis[J]. Arthritis Rheum， 2012， 64(3)： 835-842.
[16] DE VITA S， QUARTUCCIO L， ISOLA M， et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis[J]. Arthritis Rheum， 2012， 64(3)： 843-853.
[17] KETTERER N，COIFFIER B， THIEBLEMONT C， et al. PhaseⅢstudy of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B)[J]. Ann Oncol， 2012， 24(4)：1032-1037.
, 百拇医药
[18] GREENWALD MW， SHERGY WJ， KAINE JL， et al. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis[J]. Arthritis Rheum，2011， 63(3)： 622-632.
[19] MEIJER JM， MEINERS PM， VISSINK A， et al. Effectiveness of rituximab treatment in primary Sj?gren’s syndrome[J]. Arthritis Rheum， 2010， 62(4)： 960-968., http://www.100md.com(白浩 孙朴 陈霞)